

**UNITED STATES BANKRUPTCY COURT  
SOUTHERN DISTRICT OF NEW YORK**

In re:

PURDUE PHARMA L.P., *et al.*,

Debtors.<sup>1</sup>

Chapter 11

Case No. 19-23649 (RDD)

(Jointly Administered)

**THIRTEENTH MONTHLY FEE STATEMENT OF FTI CONSULTING, INC. FOR  
COMPENSATION FOR SERVICES RENDERED AND REIMBURSEMENT OF  
EXPENSES INCURRED AS FINANCIAL ADVISOR TO THE AD HOC COMMITTEE  
OF GOVERNMENTAL AND OTHER CONTINGENT LITIGATION CLAIMANTS FOR  
THE PERIOD FROM OCTOBER 1, 2020 THROUGH OCTOBER 31, 2020**

Name of Applicant:	FTI Consulting, Inc.
Authorized to provide Professional Services to:	Ad Hoc Committee of Governmental and Other Contingent Litigation Claimants
Date of Order Approving Debtors' Payment of Fees and Expenses of Applicant:	December 2, 2019 [ECF No. 553]
Period for which compensation and reimbursement is sought:	October 1, 2020 through October 31, 2020
Monthly Fees Incurred:	\$356,078.50

---

1. The Debtors in these chapter 11 cases, along with the last four digits of each Debtor's registration number in the applicable jurisdiction, are as follows: Purdue Pharma L.P. (7484), Purdue Pharma Inc. (7486), Purdue Transdermal Technologies L.P. (1868), Purdue Pharma Manufacturing L.P. (3821), Purdue Pharmaceuticals L.P. (0034), Imbrium Therapeutics L.P. (8810), Adlon Therapeutics L.P. (6745), Greenfield BioVentures L.P. (6150), Seven Seas Hill Corp. (4591), Ophir Green Corp. (4594), Purdue Pharma of Puerto Rico (3925), Avrio Health L.P. (4140), Purdue Pharmaceutical Products L.P. (3902), Purdue Neuroscience Company (4712), Nayatt Cove Lifesciences Inc. (7805), Button Land L.P. (7502), Rhodes Associates L.P. (N/A), Paul Land Inc. (7425), Quidnick Land L.P. (7584), Rhodes Pharmaceuticals L.P. (6166), Rhodes Technologies (7143), UDF LP (0495), SVC Pharma LP (5717), and SVC Pharma Inc. (4014). The Debtors' corporate headquarters is located at One Stamford Forum, 201 Tresser Boulevard, Stamford, CT 06901.

Monthly Expenses Incurred: \$0.00

Total Fees and Expenses Due: \$356,078.50

This is a: X monthly \_\_\_\_\_ interim \_\_\_\_\_ final application

**PRIOR APPLICATIONS:**

Docket No./Filed	Compensation Period	Requested		Approved	
		Fees	Expenses	Fees	Expenses
Docket No. 635 Filed On 12/9/2019	9/19/2019 – 10/31/2019	\$778,791.50	\$680.61	\$771,291.50	\$680.61
Docket No. 741 Filed On 1/13/2020	11/1/2019 – 11/30/2019	\$827,575.00	\$899.41	\$820,075.00	\$899.41
Docket No. 852 Filed on 2/20/2020	12/1/2019 – 12/31/2019	\$802,036.50	\$2,284.19	\$794,536.50	\$2,284.19
Docket No. 916 Filed on 3/12/2020	1/1/2020 – 1/31/2020	\$774,662.00	\$11,530.84	\$767,162.00	\$11,530.84
Docket No. 1090 Filed on 4/27/2020	2/1/2020 – 2/29/2020	\$615,089.00	\$6,141.22	\$610,714.00	\$6,141.22
Docket No. 1171 Filed on 5/19/2020	3/1/2020 – 3/31/2020	\$561,863.50	\$67.08	\$557,488.50	\$67.08
Docket No. 1251 Filed on 6/10/2020	4/1/2020 – 4/30/2020	\$428,303.00	\$1,732.28	\$423,928.00	\$1,732.28
Docket No. 1379 Filed on 7/13/2020	5/1/2020 – 5/31/2020	\$303,367.00	\$4,325.26	\$298,992.00	\$4,325.26
Docket No. 1651 Filed on 9/2/2020	6/1/2020 – 6/30/2020	\$374,753.00	\$96.90	\$ 299,802.60	\$ 96.90
Docket No. 1725 Filed on 9/25/2020	7/1/2020 – 7/31/2020	\$446,975.50	\$0.00	\$357,580.40	\$0.00
Docket No. 1850 Filed on 10/26/2020	8/1/2020 – 8/31/2020	\$261,092.00	\$108.25	\$ -	\$ -
Docket No. 1950 Filed on 10/26/2020	9/1/2020 – 9/30/2020	\$357,546.50	\$0.00	\$ -	\$ -

Note: The fee examiner's agreed upon reductions of \$30,000 and \$17,500 were allocated evenly across fees from the first and second interim period, respectively.

This statement (the “**Fee Statement**”) of FTI Consulting, Inc. (together with its wholly owned subsidiaries and independent contractors, “**FTI**”) as financial advisor to the Ad Hoc Committee of Governmental and Other Contingent Litigation Claimants of Purdue Pharma L.P., *et al.* (the “**Committee**”) is submitted in accordance with the *Order Establishing Procedures for Interim Compensation and Reimbursement of Expenses for Retained Professionals* [ECF No. 529] and the *Order Authorizing the Debtors to Assume the Reimbursement Agreement and Pay the Fees and Expenses of the Ad Hoc Committee’s Professionals* [ECF No. 553] entered on November 21, 2019 and December 2, 2019, respectively, (the “**Orders**”). In support of this Fee Statement, FTI respectfully states as follows.

1. The fees and expenses for the period from October 1, 2020 through and including October 31, 2020 (the “**Fee Period**”) amount to:

Professional Fees	\$356,078.50
Expenses	<u>0.00</u>
<b>TOTAL</b>	<b><u>\$356,078.50</u></b>

2. In accordance with the Orders, FTI has separately recorded its fees in connection with or relating to the allocation of value among the Debtors’ creditors (the “**Allocation Fees**”) and has not, to the best of its knowledge, included Allocation Fees in this Fee Statement. If no timely and proper objection is made by a party-in-interest within fourteen (14) days after service of this Fee Statement, the Debtors are authorized to pay 80% of professional fees and 100% of out-of-pocket expenses. These amounts are presented below.

Professional Fees at 80%	\$284,862.80
Expenses at 100%	<u>0.00</u>
<b>TOTAL</b>	<b><u>\$284,862.80</u></b>

3. The professionals providing services, hourly billing rates, the aggregate hours worked by each professional, and the aggregate hourly fees for each professional during the Fee Period are set forth on the schedule annexed hereto as **Exhibit “A.”**
4. A summary of aggregate hours worked and aggregate hourly fees for each task code during the Fee Period is set forth on the schedule annexed hereto as **Exhibit “B.”**
5. Detailed time entry by task code during the Fee Period is set forth on the schedule annexed hereto as **Exhibit “C.”**
6. FTI reserves the right to request, in subsequent fee statements and applications, reimbursement of any additional expenses incurred during the Fee Period, as such expenses may not have been captured to date in FTI’s billing system.

#### **NOTICE AND OBJECTION PROCEDURES**

7. Objections to this Fee Statement, if any, must be filed with the Court and served upon the Notice Parties so as to be received no later than January 1, 2021 (the **“Objection Deadline”**), setting forth the nature of the objection and the amount of fees or expenses at issue (an **“Objection”**).
8. If no objections to this Fee Statement are filed and served as set forth above, the Debtors shall promptly pay eighty percent (80%) of the fees and one hundred percent (100%) of the expenses identified herein.
9. If an objection to this Fee Statement is received on or before the Objection Deadline, the Debtors shall withhold payment of that portion of this Fee Statement to which the objection is directed and promptly pay the remainder of the fees and disbursements in the percentages set forth above. To the extent such an objection is not resolved, it shall be

preserved and scheduled for consideration at the next interim fee application hearing to be heard by the Court.

Dated: New York, New York  
December XX, 2020

FTI CONSULTING, INC.  
Financial Advisors to the Ad Hoc Committee of  
Governmental and Other Contingent Litigation  
Claimants of Purdue Pharma L.P.

By: /s/ Matthew Diaz  
Matthew Diaz, Senior Managing Director  
Three Times Square, 10<sup>th</sup> Floor  
New York, New York 10036  
Telephone: (212) 499-3611  
Email: matt.diaz@fticonsulting.com

**EXHIBIT A**

**PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649  
SUMMARY OF HOURS BY PROFESSIONAL  
FOR THE PERIOD OCTOBER 1, 2020 TO OCTOBER 31, 2020**

<b>Professional</b>	<b>Position</b>	<b>Specialty</b>	<b>Billing Rate<sup>1</sup></b>	<b>Total Hours</b>	<b>Total Fees</b>
Diaz, Matthew	Senior Managing Director	Restructuring	\$ 1,085	82.2	\$ 89,187.00
Joffe, Steven	Senior Managing Director	Tax	1,125	6.0	6,750.00
Simms, Steven	Senior Managing Director	Restructuring	1,295	9.6	12,432.00
Bradley, Adam	Senior Managing Director	International Healthcare	1,160	2.0	2,320.00
Blonder, Brian	Managing Director	Intellectual Property	730	5.7	4,161.00
Suric, Emil	Senior Director	Healthcare	820	5.8	4,756.00
Bromberg, Brian	Director	Restructuring	815	165.5	134,882.50
Kim, Ye Darm	Senior Consultant	Restructuring	560	161.3	90,328.00
Kurtz, Emma	Consultant	Restructuring	415	26.8	11,122.00
Hellmund-Mora, Marili	Associate	Restructuring	280	0.5	140.00
<b>GRAND TOTAL</b>				<b>465.4</b>	<b>\$ 356,078.50</b>

1. Reflects blended hourly rates. Billing rates of international professionals have been translated to USD using the relevant spot rate.

**EXHIBIT B**

**PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649  
SUMMARY OF HOURS BY TASK  
FOR THE PERIOD OCTOBER 1, 2020 TO OCTOBER 31, 2020**

<b>Task Code</b>	<b>Task Description</b>	<b>Total Hours</b>	<b>Total Fees</b>
1	Current Operating Results & Events	9.6	\$ 5,748.00
7	Analysis of Domestic Business Plan	52.4	42,067.00
9	Analysis of Employee Comp Programs	15.7	13,949.00
10	Analysis of Tax Issues	12.2	11,816.50
16	Analysis, Negotiate and Form of POR & DS	155.2	116,710.00
18	Review of Historical Transactions	141.3	105,777.00
19	Case Management	3.1	1,660.50
20	General Mtgs with Debtor & Debtors' Prof	1.1	1,193.50
21	General Meetings with Counsel and/or Ad Hoc Committee	13.7	13,352.50
22	Meetings with Other Parties	4.8	5,208.00
24	Preparation of Fee Application	21.8	12,955.00
28	Review of IAC Business Plan	34.5	25,641.50
<b>GRAND TOTAL<sup>1</sup></b>		<b>465.4</b>	<b>\$ 356,078.50</b>

1. Billing rates of international professionals have been translated to USD using the relevant spot rate.

**EXHIBIT C**  
**PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649**  
**DETAIL OF TIME ENTRIES**  
**FOR THE PERIOD OCTOBER 1, 2020 TO OCTOBER 31, 2020**

<b>Task Category</b>	<b>Date</b>	<b>Professional</b>	<b>Hours</b>	<b>Activity</b>
1	10/5/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	10/6/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	10/7/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	10/8/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	10/9/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	10/12/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	10/13/2020	Simms, Steven	1.7	Participate in call with Debtor on go-forward operations issues.
1	10/13/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	10/14/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	10/15/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	10/16/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	10/19/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	10/20/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	10/21/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	10/22/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	10/23/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	10/26/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	10/27/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	10/28/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	10/28/2020	Diaz, Matthew	0.4	Review news coverage on the DOJ settlement.
1	10/29/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	10/30/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
<b>1 Total</b>			<b>9.6</b>	
7	9/29/2020	Kim, Ye Darm	0.6	Participate in call re: OxyContin sensitivity cases.
7	9/29/2020	Kim, Ye Darm	0.4	Review OxyContin sales forecasts for high case scenarios.
7	10/1/2020	Kim, Ye Darm	1.0	Participate in call with Debtors' advisors re: OxyContin forecasts.
7	10/1/2020	Bromberg, Brian	0.8	Participate in call with Debtors on the updated OxyContin forecast.
7	10/1/2020	Diaz, Matthew	0.7	Participate in call with the Debtors to discuss the updated OxyContin forecast.
7	10/1/2020	Suric, Emil	2.8	Prepare analyses re: OxyContin forecast sensitivity relative to Debtors' plan.
7	10/1/2020	Bromberg, Brian	0.3	Prepare for call with Debtors on the updated OxyContin forecast.
7	10/1/2020	Suric, Emil	0.8	Prepare OxyContin forecast sensitivity presentation.
7	10/1/2020	Diaz, Matthew	1.1	Review the Debtors' updated domestic business plan.
7	10/11/2020	Kim, Ye Darm	0.9	Review historical OxyContin gross-to-net sales analyses.
7	10/12/2020	Kim, Ye Darm	2.2	Prepare analysis of illustrative impact of removal of OxyContin dosages.
7	10/12/2020	Bromberg, Brian	2.2	Review diligence follow up list for the NCSG.
7	10/13/2020	Bromberg, Brian	0.8	Participate in call with Committee re: Purdue go-forward strategy and Sackler Assets
7	10/13/2020	Bromberg, Brian	0.7	Participate in call with Debtors re: Purdue go-forward strategy.
7	10/14/2020	Bromberg, Brian	0.7	Review domestic business plan diligence files from the Debtors.



**EXHIBIT C**  
**PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649**  
**DETAIL OF TIME ENTRIES**  
**FOR THE PERIOD OCTOBER 1, 2020 TO OCTOBER 31, 2020**

<b>Task Category</b>	<b>Date</b>	<b>Professional</b>	<b>Hours</b>	<b>Activity</b>
7	10/14/2020	Diaz, Matthew	2.1	Review the updated Purdue business plan.
7	10/16/2020	Bromberg, Brian	3.7	Create cash flow bridge to the Debtors' new business plan.
7	10/16/2020	Bromberg, Brian	1.0	Review new business plan diligence update files from the Debtors.
7	10/17/2020	Bromberg, Brian	1.0	Finalize and distribute bridge analysis to internal team.
7	10/17/2020	Kim, Ye Darm	1.2	Prepare bridge of the updated business plan distributable value.
7	10/19/2020	Kurtz, Emma	0.5	Discuss cash flow bridge form previous business plan to latest business plan.
7	10/19/2020	Kim, Ye Darm	0.8	Participate in discussion re: domestic business plan cash flow bridge.
7	10/19/2020	Bromberg, Brian	1.3	Participate in discussion re: domestic business plan cash flow bridge.
7	10/19/2020	Bromberg, Brian	2.1	Review the domestic business plan cash flow bridge analysis.
7	10/19/2020	Diaz, Matthew	0.8	Review the updated business plan and the related exhibits to the go forward structure.
7	10/19/2020	Diaz, Matthew	1.1	Review the updated business plan bridge reconciliation.
7	10/20/2020	Bromberg, Brian	0.8	Review Debtor analysis on Rhodes savings.
7	10/20/2020	Bromberg, Brian	1.2	Review Debtor pipeline products for upcoming call.
7	10/20/2020	Kim, Ye Darm	0.6	Review Debtors' materials re: savings from the Rhodes Tech sale.
7	10/21/2020	Diaz, Matthew	0.9	Review the updated business plan analysis and related sensitivity cases.
7	10/22/2020	Bromberg, Brian	1.2	Continue review of Debtor pipeline products for upcoming call.
7	10/23/2020	Bromberg, Brian	0.7	Review Debtors' pipeline diligence with team.
7	10/26/2020	Kim, Ye Darm	0.6	Review Rhodes pipeline product forecasts.
7	10/26/2020	Bromberg, Brian	0.8	Review Rhodes pipeline product forecasts.
7	10/27/2020	Kim, Ye Darm	0.8	Participate in a call with the Debtors re: pipeline updates and current progress.
7	10/27/2020	Diaz, Matthew	0.8	Participate in a call with the Purdue management team to review the current progress made on the pipeline products.
7	10/27/2020	Suric, Emil	1.0	Participate in call re: Debtors' pipeline updates.
7	10/27/2020	Bromberg, Brian	0.7	Participate in call with Debtors on current progress of pipeline products.
7	10/27/2020	Bromberg, Brian	0.7	Review Debtors' pipeline diligence with team.
7	10/27/2020	Bromberg, Brian	1.3	Review newly uploaded dataroom documents re: PHI and PBC.
7	10/27/2020	Diaz, Matthew	0.8	Review the Debtors' latest PHI update.
7	10/27/2020	Kim, Ye Darm	1.5	Review updates on PHIs and HRT provided in the dataroom.
7	10/28/2020	Bromberg, Brian	2.4	Review analysis between business plan and cash flow presentation.
7	10/28/2020	Bromberg, Brian	0.9	Review the new Debtor presentation on PBC considerations.
7	10/30/2020	Bromberg, Brian	0.9	Continue review bridging analysis to latest PJT presentation.
7	10/30/2020	Bromberg, Brian	2.2	Review the bridge analysis to latest PJT presentation.
<b>7 Total</b>			<b>52.4</b>	
9	10/9/2020	Bromberg, Brian	0.5	Discuss the latest KEIP proposal with counsel.
9	10/9/2020	Diaz, Matthew	0.4	Participate in a call with counsel to discuss the insider compensation plans.
9	10/9/2020	Bromberg, Brian	1.0	Review KEIP and KERP support files to evaluate the updated proposal.
9	10/9/2020	Diaz, Matthew	0.7	Review the latest insider compensation plans and UCC proposal.
9	10/9/2020	Bromberg, Brian	0.9	Review the UCC's latest KEIP proposal.
9	10/9/2020	Kim, Ye Darm	1.6	Review UCC KEIP settlement proposal and compare with historical payout.
9	10/10/2020	Diaz, Matthew	0.6	Review the updated KEIP proposal.
9	10/11/2020	Diaz, Matthew	0.7	Review the latest proposed employee compensation and KEIP plans.
9	10/12/2020	Diaz, Matthew	0.9	Review the updated UCC KEIP proposal.
9	10/13/2020	Diaz, Matthew	0.6	Continue review of the KEIP proposal.
9	10/15/2020	Diaz, Matthew	0.9	Participate in a call with the UCC, company and NCSG to discuss certain KEIP and KERP participants.
9	10/15/2020	Bromberg, Brian	1.2	Participate in call with Debtor advisors re: KERP identified individuals.
9	10/16/2020	Diaz, Matthew	0.3	Participate in a call with Alix to discuss the KEIP proposal.
9	10/16/2020	Diaz, Matthew	0.8	Review the updated KEIP proposal.
9	10/18/2020	Kim, Ye Darm	0.9	Prepare analysis re: Debtors' updated KEIP proposal to prior compensation figures.
9	10/18/2020	Diaz, Matthew	0.4	Review analysis re: historical senior employee compensation comparables.
9	10/18/2020	Bromberg, Brian	0.8	Review the Debtors' counterproposal offer on KEIP figures.
9	10/18/2020	Kim, Ye Darm	0.6	Review the Debtors' KEIP counterproposal figures.
9	10/18/2020	Diaz, Matthew	0.5	Review the updated executive compensation proposal.
9	10/21/2020	Diaz, Matthew	0.4	Review the Debtors' updated KEIP proposal.
9	10/31/2020	Bromberg, Brian	1.0	Participate in call on KEIP with UCC and NCSG and prepare summary for distribution to internal team.
<b>9 Total</b>			<b>15.7</b>	
10	10/1/2020	Bromberg, Brian	0.7	Participate in tax call re: structuring considerations.

**EXHIBIT C**  
**PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649**  
**DETAIL OF TIME ENTRIES**  
**FOR THE PERIOD OCTOBER 1, 2020 TO OCTOBER 31, 2020**

<b>Task Category</b>	<b>Date</b>	<b>Professional</b>	<b>Hours</b>	<b>Activity</b>
10	10/12/2020	Bromberg, Brian	0.7	Discuss NCSG tax questions with counsel.
10	10/13/2020	Joffe, Steven	1.0	Participate in call re: IAC tax considerations.
10	10/13/2020	Joffe, Steven	1.4	Participate in call with Debtors re: tax considerations.
10	10/15/2020	Bromberg, Brian	0.5	Correspond with tax counsel on IACs tax considerations.
10	10/15/2020	Joffe, Steven	0.5	Review of post-emergence structuring presentation for potential tax issues.
10	10/21/2020	Joffe, Steven	0.5	Participate in call re: domestic business tax structuring considerations.
10	10/21/2020	Kim, Ye Darm	0.5	Review tax settlement structure presentation from BR.
10	10/27/2020	Joffe, Steven	1.0	Participate in call with committee regarding Purdue v. Sacklers tax considerations.
10	10/28/2020	Joffe, Steven	1.1	Participate in call with AHC re: tax considerations.
10	10/30/2020	Bromberg, Brian	0.3	Discuss tax diligence questions with team.
10	10/30/2020	Diaz, Matthew	0.9	Participate in a call with the AHC's tax advisors to discuss tax implications of the proposed go forward structure.
10	10/30/2020	Bromberg, Brian	0.8	Participate in call on tax strategy and considerations.
10	10/30/2020	Kim, Ye Darm	0.4	Participate in call re: potential operating tax impact analysis.
10	10/30/2020	Joffe, Steven	0.5	Participate in call with counsel re: tax calculations from operations.
10	10/30/2020	Bromberg, Brian	0.9	Review current tax considerations diligence question list.
10	10/30/2020	Bromberg, Brian	0.5	Review historical tax analyses provided to counsel.
<b>10 Total</b>			<b>12.2</b>	
16	10/1/2020	Bromberg, Brian	2.1	Complete preparation of draft mediation preparation materials.
16	10/1/2020	Kim, Ye Darm	0.6	Continue processing revisions for draft slides for presentation re: Mediation Phase 2 prep.
16	10/1/2020	Kim, Ye Darm	2.1	Continue to prepare draft slides for presentation re: Mediation Phase 2 prep.
16	10/1/2020	Bromberg, Brian	3.1	Create mediation preparation materials for the committee.
16	10/1/2020	Kim, Ye Darm	0.4	Participate in call re: presentation for Mediation Phase 2 prep.
16	10/1/2020	Bromberg, Brian	0.9	Participate in discussion re: draft mediation preparation materials.
16	10/1/2020	Kim, Ye Darm	0.6	Participate in internal call for workplan on the presentation re: Mediation Phase 2 prep.
16	10/1/2020	Kim, Ye Darm	2.2	Prepare draft slides for presentation re: Mediation Phase 2 prep.
16	10/1/2020	Kim, Ye Darm	2.8	Process revisions and updated draft slides for presentation re: Mediation Phase 2 prep.
16	10/1/2020	Kim, Ye Darm	1.9	Process revisions to draft slides for presentation re: Mediation Phase 2 prep.
16	10/1/2020	Kim, Ye Darm	0.8	Review post tax values of assets re: Mediation Phase 2 preparation deck.
16	10/1/2020	Bromberg, Brian	3.2	Review the latest mediation update presentation to the AHC.
16	10/1/2020	Kim, Ye Darm	0.7	Update draft slides for presentation re: Mediation Phase 2 prep.
16	10/2/2020	Kim, Ye Darm	0.5	Participate in discussion re: Mediation Phase 2 Report.
16	10/2/2020	Bromberg, Brian	1.0	Participate in discussion with team re: revisions to the latest mediation presentation.
16	10/2/2020	Bromberg, Brian	1.9	Perform QC on Mediation Phase 2 presentation.
16	10/2/2020	Kim, Ye Darm	1.2	Prepare updated value scenarios for latest OxyContin forecast figures.
16	10/2/2020	Kim, Ye Darm	1.4	Process additional revisions to the draft slides for presentation re: Mediation Phase 2 prep.
16	10/2/2020	Bromberg, Brian	2.1	Process revisions on the latest mediation presentation.
16	10/2/2020	Kim, Ye Darm	2.3	Process revisions to the draft slides for presentation re: Mediation Phase 2 prep.
16	10/2/2020	Diaz, Matthew	2.6	Review and edit presentation to the AHC subcommittee on the Sackler mediation.
16	10/4/2020	Diaz, Matthew	1.4	Review the updated presentation on the Sackler mediation.
16	10/5/2020	Diaz, Matthew	1.1	Participate in a call with the AHC professionals to discuss the Sackler mediation report.
16	10/5/2020	Kim, Ye Darm	1.0	Participate in call with Counsel re: Mediation Phase 2 overview presentation.
16	10/5/2020	Bromberg, Brian	1.4	Participate in call with Counsel re: mediation preparation.
16	10/5/2020	Kim, Ye Darm	2.4	Process updates to Mediation Phase 2 overview presentation.
16	10/5/2020	Simms, Steven	0.6	Review draft presentation on Sackler asset diligence and current status of mediation.
16	10/5/2020	Bromberg, Brian	1.1	Review PEO information in mediation presentation slides.
16	10/5/2020	Diaz, Matthew	1.9	Review the updated draft of the Sackler mediation report.
16	10/5/2020	Bromberg, Brian	1.2	Review updated revisions on mediation prep slides.
16	10/6/2020	Bromberg, Brian	1.3	Participate in call with counsel re: mediation preparation and draft presentation.
16	10/6/2020	Kim, Ye Darm	1.6	Process updates to Mediation Phase 2 overview presentation.
16	10/6/2020	Bromberg, Brian	2.0	Review and provide revisions to the mediation presentation.
16	10/6/2020	Simms, Steven	0.9	Review draft presentation on mediation considerations.
16	10/6/2020	Diaz, Matthew	1.3	Review the updated report to the committee on the Sackler mediation.
16	10/7/2020	Kim, Ye Darm	1.7	Participate in call re: Purdue Mediation Phase 2 overview presentation.

**EXHIBIT C**  
**PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649**  
**DETAIL OF TIME ENTRIES**  
**FOR THE PERIOD OCTOBER 1, 2020 TO OCTOBER 31, 2020**

<b>Task Category</b>	<b>Date</b>	<b>Professional</b>	<b>Hours</b>	<b>Activity</b>
16	10/7/2020	Bromberg, Brian	1.0	Participate in call re: status of draft mediation presentation.
16	10/7/2020	Diaz, Matthew	1.7	Participate in meeting with the AHC subcommittee to present report on topics related to the Sackler mediation.
16	10/7/2020	Diaz, Matthew	0.5	Preparation for the meeting with the AHC subcommittee on the Sackler mediation topics.
16	10/8/2020	Kim, Ye Darm	0.9	Process revisions to Mediation Phase 2 overview presentation.
16	10/8/2020	Bromberg, Brian	0.7	Review revisions incorporated into the latest draft mediation presentation.
16	10/9/2020	Bromberg, Brian	0.7	Discuss follow-up information re: mediation considerations for the NCSG.
16	10/9/2020	Kim, Ye Darm	2.0	Participate in call with AHC/NCSG re: Mediation Phase 2.
16	10/9/2020	Bromberg, Brian	0.5	Participate in call with Debtors re: sale process.
16	10/9/2020	Bromberg, Brian	2.3	Participate in call with NCSG re: mediation considerations.
16	10/9/2020	Diaz, Matthew	0.5	Participate in call with the UCC to discuss proposed inbound buyer interest.
16	10/10/2020	Bromberg, Brian	1.2	Discuss and compile follow-up information for NCSG re: mediation considerations.
16	10/11/2020	Bromberg, Brian	1.8	Participate in discussion re: follow up information for NCSG on mediation considerations.
16	10/11/2020	Diaz, Matthew	1.1	Review follow-ups from call with the NCSG re: mediation.
16	10/12/2020	Kim, Ye Darm	0.7	Participate in call re: Mediation Phase 2 overview follow ups.
16	10/12/2020	Bromberg, Brian	1.1	Participate in call with counsel and bankers re: Mediation Phase 2.
16	10/12/2020	Bromberg, Brian	1.1	Participate in call with internal team re: Mediation Phase 2.
16	10/12/2020	Kim, Ye Darm	0.6	Participate in internal call re: Mediation Phase 2 presentation follow ups.
16	10/12/2020	Diaz, Matthew	0.9	Review the updated presentation to the AHC on the Sackler mediation.
16	10/13/2020	Diaz, Matthew	1.6	Participate in a call with the Debtors to discuss their proposed post emergence structure.
16	10/13/2020	Kim, Ye Darm	1.1	Participate in call re: Mediation Phase 2 Presentation.
16	10/13/2020	Kim, Ye Darm	1.5	Participate in call with Debtors re: go-forward business considerations.
16	10/13/2020	Kim, Ye Darm	1.2	Process revisions to the Mediation Phase 2 overview presentation.
16	10/15/2020	Kim, Ye Darm	0.4	Process revisions to Mediation Phase 2 overview presentation.
16	10/16/2020	Kim, Ye Darm	1.9	Assist preparation of analysis re: distributable value scenarios for trust.
16	10/16/2020	Diaz, Matthew	1.0	Participate in a call with Houlihan and counsel to discuss post emergence trust structures in connection with mediation.
16	10/16/2020	Diaz, Matthew	0.9	Participate in a call with Houlihan to discuss possible post emergence structures.
16	10/16/2020	Bromberg, Brian	1.2	Participate in call re: trust governance considerations with counsel.
16	10/16/2020	Kurtz, Emma	1.0	Participate in call to review proposed term sheet and impact to distributable value.
16	10/16/2020	Kim, Ye Darm	1.0	Participate in call with Counsel and HL re: trust considerations.
16	10/16/2020	Kim, Ye Darm	0.6	Participate in call with HL re: distributable value assumptions.
16	10/16/2020	Kim, Ye Darm	0.6	Participate in call with HL re: trust considerations.
16	10/16/2020	Kim, Ye Darm	1.2	Review analysis re: distributable value bridge to Debtors' latest plan.
16	10/16/2020	Kim, Ye Darm	0.9	Review distributable value model for prior assumptions.
16	10/18/2020	Diaz, Matthew	1.5	Participate in a call with the AHC professionals to discuss the proposed trust go-forward structure.
16	10/18/2020	Bromberg, Brian	1.7	Participate in call with counsel re: trust structuring considerations.
16	10/19/2020	Diaz, Matthew	0.6	Participate in a call with the AHC's professionals to discuss the proposed go-forward term sheet structure.
16	10/19/2020	Bromberg, Brian	1.3	Participate in call with counsel re: governance issues.
16	10/19/2020	Simms, Steven	0.6	Participate in meeting re: presentation on corporate governance items.
16	10/19/2020	Kim, Ye Darm	2.1	Prepare analysis of shortfall/surplus of distributable value from insurance and cash contributions.
16	10/19/2020	Bromberg, Brian	0.9	Review Houlihan analysis on governance structure considerations.
16	10/19/2020	Diaz, Matthew	0.5	Review the proposed go-forward trust structure term sheet.
16	10/20/2020	Kim, Ye Darm	1.8	Continue processing updates to surplus/shortfall analysis for distributable value.
16	10/20/2020	Kim, Ye Darm	0.6	Correspond with HL re: surplus/shortfall distributable value analysis.
16	10/20/2020	Bromberg, Brian	0.7	Prepare and send to Houlihan comments on trust structure analysis.
16	10/20/2020	Kim, Ye Darm	1.2	Prepare updated presentation slide re: surplus/short analysis of distributable value.
16	10/20/2020	Kim, Ye Darm	0.8	Process revisions to the surplus/shortfall distributable value analysis.
16	10/20/2020	Kim, Ye Darm	0.9	Process updates to surplus/shortfall distributable value analysis per call with HL.
16	10/20/2020	Kim, Ye Darm	1.1	Process updates to the surplus/shortfall distributable value analysis.
16	10/20/2020	Bromberg, Brian	3.1	Review and edit the trust structure cash flow analysis.

**EXHIBIT C**  
**PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649**  
**DETAIL OF TIME ENTRIES**  
**FOR THE PERIOD OCTOBER 1, 2020 TO OCTOBER 31, 2020**

<b>Task Category</b>	<b>Date</b>	<b>Professional</b>	<b>Hours</b>	<b>Activity</b>
16	10/20/2020	Kim, Ye Darm	0.3	Review calculation of asset sale figures in HL presentation for distributable value analysis.
16	10/20/2020	Kim, Ye Darm	0.9	Review HL presentation on governance/trust structure.
16	10/20/2020	Bromberg, Brian	0.7	Review Houlihan's valuation analysis for distributable value.
16	10/20/2020	Kim, Ye Darm	1.3	Update the surplus/shortfall analysis for expected settlements.
16	10/21/2020	Bromberg, Brian	0.5	Discuss value shortfall analysis with Houlihan.
16	10/21/2020	Diaz, Matthew	1.0	Participate in a call with the AHC professionals to discuss the go-forward trust emergence structure.
16	10/21/2020	Bromberg, Brian	1.0	Participate in call on governance considerations with Counsel.
16	10/21/2020	Kim, Ye Darm	1.0	Participate in call re: HL Governance/Trust structure presentation.
16	10/21/2020	Bromberg, Brian	0.8	Participate in discussion re: distributable value analysis with team.
16	10/21/2020	Kim, Ye Darm	0.4	Participate in discussion with HL re: updated distributable value surplus/shortfall analysis.
16	10/21/2020	Kim, Ye Darm	0.9	Prepare updated presentation slide for updates to the distributable value analysis.
16	10/21/2020	Kim, Ye Darm	1.1	Process revisions to the surplus/shortfall distributable value analysis for trust structure considerations.
16	10/21/2020	Kim, Ye Darm	1.3	Process updates to distributable value surplus/shortfall analysis for settlement estimates.
16	10/21/2020	Kim, Ye Darm	0.6	Process updates to the distributable value surplus/shortfall analysis for the DOJ settlement.
16	10/21/2020	Bromberg, Brian	1.5	Review and process revisions to distributable value analysis based on latest discussions.
16	10/21/2020	Kim, Ye Darm	2.4	Review the DOJ settlement materials to incorporate in latest distributable value analysis.
16	10/21/2020	Bromberg, Brian	2.2	Review the latest distributable value analysis and provide revisions.
16	10/21/2020	Diaz, Matthew	0.6	Review the proposed DOJ settlement and impact on available proceeds.
16	10/21/2020	Diaz, Matthew	0.9	Review the updated go-forward trust/governance presentation.
16	10/21/2020	Kim, Ye Darm	0.7	Update presentation for latest distributable value surplus/shortfall analysis.
16	10/22/2020	Diaz, Matthew	0.5	Review the updated trust presentation on the go-forward structure.
16	10/23/2020	Bromberg, Brian	1.1	Participate in call on governance with the subcommittee.
16	10/23/2020	Diaz, Matthew	1.5	Participate in call re: Presentation to the AHC subcommittee to discuss go forward Purdue.
16	10/27/2020	Simms, Steven	0.8	Participate in call re: Sackler related diligence and investigation issues with case professionals.
16	10/27/2020	Kim, Ye Darm	1.0	Participate in meeting re: mediation strategy.
16	10/27/2020	Bromberg, Brian	0.9	Participate in professionals call re: mediation strategy.
16	10/27/2020	Bromberg, Brian	0.4	Summarize call re: mediation strategy for internal distribution.
16	10/28/2020	Kim, Ye Darm	1.8	Prepare bridges of distributable value between sale case scenarios.
16	10/28/2020	Kim, Ye Darm	0.8	Review latest draft of the HL structure presentation.
16	10/28/2020	Bromberg, Brian	0.5	Review the DOJ settlement terms on impact to distributable value.
16	10/28/2020	Bromberg, Brian	0.9	Review the latest trust structure presentation.
16	10/28/2020	Diaz, Matthew	0.5	Review the updated post emergence cash flow presentation.
16	10/29/2020	Bromberg, Brian	2.1	Participate in call with NCSG re: governance structure.
16	10/29/2020	Kim, Ye Darm	1.2	Prepare additional bridge analysis of sale case scenarios.
16	10/29/2020	Kim, Ye Darm	2.6	Prepare bridge analysis to PJT's distributable value estimates.
16	10/29/2020	Kim, Ye Darm	0.9	Review PJT's presentation on distributable value estimates.
16	10/29/2020	Diaz, Matthew	0.6	Review PJT's updated distributable value analysis presentation.
16	10/30/2020	Diaz, Matthew	0.8	Participate in a call with the AHC Professionals to discuss the proposed trust structure.
16	10/30/2020	Bromberg, Brian	1.1	Participate in call re: mediation considerations.
16	10/30/2020	Kim, Ye Darm	0.6	Prepare responses re: variance to PJT distributable value estimate.
16	10/30/2020	Kim, Ye Darm	1.6	Process revisions to bridge analysis re: PJT distributable value estimates.
16	10/30/2020	Kim, Ye Darm	0.9	Reconcile variances of the bridge analysis re: PJT distributable value estimates.
16	10/30/2020	Kim, Ye Darm	0.8	Review surplus/shortfall value analysis for potential tax impacts.
16	10/30/2020	Diaz, Matthew	1.1	Review the updated company recovery analysis and reconcile to existing work.
<b>16 Total</b>			<b>155.2</b>	
18	9/29/2020	Kim, Ye Darm	0.5	Participate in call re: reconciliation of AlixPartners transfers report.
18	9/29/2020	Kim, Ye Darm	2.8	Process revisions and updates to the asset and transfers diligence presentation.

**EXHIBIT C**  
**PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649**  
**DETAIL OF TIME ENTRIES**  
**FOR THE PERIOD OCTOBER 1, 2020 TO OCTOBER 31, 2020**

<b>Task Category</b>	<b>Date</b>	<b>Professional</b>	<b>Hours</b>	<b>Activity</b>
18	9/30/2020	Kim, Ye Darm	2.3	Analyze the B-side asset excel spreadsheets for balance sheet items and reconciliation to report.
18	9/30/2020	Kim, Ye Darm	2.2	Process revisions to the Sackler Assets and Transfers diligence presentation.
18	9/30/2020	Kim, Ye Darm	1.2	Process revisions to the Sackler Assets and Transfers presentation for new B-side information.
18	10/5/2020	Kurtz, Emma	1.3	Participate in call with Committee advisors to discuss Sackler asset reports and sales process.
18	10/5/2020	Diaz, Matthew	0.7	Review of the updated causes of action analysis against the Sacklers.
18	10/6/2020	Diaz, Matthew	0.5	Participate in call with the UCC and KL to discuss their analysis on the causes of action.
18	10/12/2020	Bromberg, Brian	1.0	Discuss A Side Sackler asset transfers with team.
18	10/12/2020	Bromberg, Brian	1.4	Follow up with Debtors and Counsel on outstanding diligence items re: historical transfers.
18	10/12/2020	Diaz, Matthew	0.6	Participate in a call with the counsel to discuss the A side transfers.
18	10/12/2020	Kim, Ye Darm	0.8	Participate in call re: A-Side Assets diligence.
18	10/12/2020	Kurtz, Emma	1.0	Participate in call with Counsel re: A-side net asset reports and historical cash transfers.
18	10/12/2020	Bromberg, Brian	1.9	Review A Side Sackler asset transfer files.
18	10/12/2020	Kurtz, Emma	0.9	Review Sackler net asset reports and follow-ups.
18	10/12/2020	Diaz, Matthew	1.7	Review the A side cash transfers among individuals and trusts.
18	10/13/2020	Kurtz, Emma	0.9	Analyze Sackler A side and B side net asset reports to evaluate how distributions and asset values tie.
18	10/13/2020	Kurtz, Emma	0.3	Discuss internally re: Sackler A side net asset reports and proposed analysis of transfers.
18	10/13/2020	Bromberg, Brian	0.6	Discuss Sackler transfers and asset diligence workstreams with team.
18	10/13/2020	Bromberg, Brian	0.6	Perform review of a specific Sackler investment.
18	10/13/2020	Bromberg, Brian	0.4	Perform revision and prepare revisions re: Sackler assets diligence presentation.
18	10/13/2020	Kim, Ye Darm	2.8	Prepare summary analysis of A-side historical cash flows.
18	10/13/2020	Kim, Ye Darm	1.1	Process updates to summary slides re: A-side cash flows.
18	10/13/2020	Bromberg, Brian	1.5	Review A side diligence presentation summary.
18	10/13/2020	Bromberg, Brian	1.0	Review and provide revisions to the A side asset diligence summary.
18	10/13/2020	Bromberg, Brian	1.9	Review B Side cash transfers analysis file.
18	10/13/2020	Bromberg, Brian	2.1	Review the B Side net asset presentation supporting file.
18	10/14/2020	Kim, Ye Darm	3.2	Continue preparing summary analysis of A-side distributions.
18	10/14/2020	Bromberg, Brian	2.2	Continue review and provide revisions on A side transfers diligence analysis.
18	10/14/2020	Bromberg, Brian	1.0	Finalize and distribute A side transfers diligence slides for upcoming call.
18	10/14/2020	Bromberg, Brian	1.3	Participate in call with team on A side assets and transfers.
18	10/14/2020	Bromberg, Brian	0.5	Participate in discussion of transfers diligence workplan with team.
18	10/14/2020	Kim, Ye Darm	0.6	Participate in discussion re: A-side cash flow analysis.
18	10/14/2020	Kim, Ye Darm	0.5	Participate in discussion re: next steps for A-side analysis.
18	10/14/2020	Kurtz, Emma	1.1	Participate in internal call re: Sackler asset reports and historical distributions workstreams.
18	10/14/2020	Simms, Steven	0.4	Participate in internal correspondence re: Sackler diligence items.
18	10/14/2020	Diaz, Matthew	3.1	Perform detailed review of the A side historical transfers analysis.
18	10/14/2020	Bromberg, Brian	1.5	Perform review of A side cash transfers supporting file.
18	10/14/2020	Kurtz, Emma	1.3	Prepare analysis of A side Sackler family members and trusts asset and net asset value as of September 2019.
18	10/14/2020	Kim, Ye Darm	3.4	Prepare transfers summary analysis for A-side distributions.
18	10/14/2020	Kim, Ye Darm	1.2	Process updates to analysis of A-side distributions per internal comments.
18	10/14/2020	Bromberg, Brian	0.5	Review and provide revisions on A side transfers diligence analysis.
18	10/15/2020	Bromberg, Brian	0.8	Continue review of A side cash transfers diligence analysis.
18	10/15/2020	Bromberg, Brian	0.9	Continue review of A side cash transfers diligence analysis.
18	10/15/2020	Kim, Ye Darm	1.2	Participate in call re: A-side distributions analysis.
18	10/15/2020	Bromberg, Brian	1.1	Participate in discussion on A side cash transfers with team.
18	10/15/2020	Diaz, Matthew	1.2	Perform review of the updated A side transfers analysis.
18	10/15/2020	Kim, Ye Darm	1.9	Prepare an updated question list re: A-side distributions.
18	10/15/2020	Kim, Ye Darm	0.7	Process updates to A-side distributions diligence question list.
18	10/15/2020	Bromberg, Brian	0.6	Review A side cash transfers supporting file.

**EXHIBIT C**  
**PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649**  
**DETAIL OF TIME ENTRIES**  
**FOR THE PERIOD OCTOBER 1, 2020 TO OCTOBER 31, 2020**

<b>Task Category</b>	<b>Date</b>	<b>Professional</b>	<b>Hours</b>	<b>Activity</b>
18	10/15/2020	Kurtz, Emma	0.5	Review A side net asset reports and historical transfers analysis with team to identify next steps.
18	10/15/2020	Bromberg, Brian	0.9	Review and finalize draft of A side analysis for distribution to internal team.
18	10/16/2020	Bromberg, Brian	1.0	Conduct review of the B side transfers support file.
18	10/16/2020	Bromberg, Brian	1.2	Participate in discussion on transfers diligence with internal team.
18	10/16/2020	Kim, Ye Darm	0.6	Participate in discussion re: B-side transfers analysis.
18	10/16/2020	Kurtz, Emma	0.9	Participate in internal discussion re: B side net asset reports and balance sheets.
18	10/16/2020	Bromberg, Brian	1.0	Prepare for call with team re: workstreams on transfers diligence and net asset reports.
18	10/16/2020	Kim, Ye Darm	1.3	Prepare updated summary slides re: latest A-side distributions analysis.
18	10/16/2020	Kim, Ye Darm	0.6	Process updates to question list re: A-side distributions.
18	10/16/2020	Kurtz, Emma	0.3	Review outstanding items related to Sackler net asset reports and historical transfers with team.
18	10/16/2020	Bromberg, Brian	0.8	Review the B Side net asset reports and balance sheets file.
18	10/16/2020	Diaz, Matthew	0.9	Review the B side transfer analysis and financial statement disclosures.
18	10/16/2020	Bromberg, Brian	1.2	Summarize draft diligence responses to outstanding transfers workstream items.
18	10/19/2020	Bromberg, Brian	0.8	Create proposed responses list to NCSG questions on transfers diligence.
18	10/19/2020	Simms, Steven	1.2	Participate in call re: presentation on Sackler distributions and transfers.
18	10/19/2020	Diaz, Matthew	1.0	Participate in call with the UCC and other key stakeholders to discuss the non- cash transfers.
18	10/19/2020	Bromberg, Brian	1.5	Participate in call with UCC re: non cash transfers.
18	10/19/2020	Kim, Ye Darm	1.0	Participate in meeting re: non-cash transfers analysis by the UCC.
18	10/19/2020	Kim, Ye Darm	0.8	Review implied royalty rates from UCC's non-cash transfers analysis.
18	10/19/2020	Bromberg, Brian	1.3	Review revised question list for A Side Sacklers.
18	10/19/2020	Diaz, Matthew	0.6	Review the UCC's non-cash transfer report.
18	10/19/2020	Kim, Ye Darm	1.7	Review the UCC's non-cash transfers analysis presentation.
18	10/19/2020	Bromberg, Brian	1.3	Review UCC presentation on non cash transfers.
18	10/19/2020	Kim, Ye Darm	0.8	Review updated diligence question list re: A-side distributions.
18	10/21/2020	Bradley, Adam	2.0	Review considerations re: OxyContin royalty comparables.
18	10/22/2020	Bromberg, Brian	1.1	Create follow up question list re: B side transfers.
18	10/22/2020	Bromberg, Brian	1.2	Discuss B side net asset report and transfers with internal team.
18	10/22/2020	Diaz, Matthew	1.1	Participate in a call with Huron and Province to discuss the B side transfer analysis.
18	10/22/2020	Bromberg, Brian	0.8	Participate in call with Huron re: Side B transfers.
18	10/22/2020	Bromberg, Brian	1.7	Prepare for call with Sackler advisors on B side transfers.
18	10/22/2020	Diaz, Matthew	0.4	Review next steps and workplan from call with Sackler advisors and UCC on the B side analysis.
18	10/22/2020	Diaz, Matthew	2.2	Review the B side transfers analysis.
18	10/22/2020	Diaz, Matthew	1.3	Review the Sackler B side net asset report.
18	10/23/2020	Kim, Ye Darm	2.6	Continue to prepare comparative analysis of AlixPartners' cash transfer report and UCC analysis.
18	10/23/2020	Bromberg, Brian	1.9	Discuss UCC non cash transfers report with team.
18	10/23/2020	Kim, Ye Darm	0.6	Participate in call re: UCC transfers analysis review.
18	10/23/2020	Kurtz, Emma	0.4	Participate in internal discussion re: comparison of the UCC non-cash transfers report to the Alix report to tie to financial information received.
18	10/23/2020	Kim, Ye Darm	1.8	Prepare comparative analysis to AlixPartners' non-cash transfers report and UCC analysis.
18	10/23/2020	Kim, Ye Darm	1.9	Prepare list of diligence questions re: UCC transfers review.
18	10/23/2020	Bromberg, Brian	1.5	Review Province question list on transfer diligence and provide revisions.
18	10/23/2020	Diaz, Matthew	1.7	Review the UCC's non cash transfer report and related next steps.
18	10/23/2020	Bromberg, Brian	1.5	Review UCC presentation on non cash transfers.
18	10/23/2020	Kim, Ye Darm	0.9	Review UCC's Transfers Analysis report.
18	10/26/2020	Bromberg, Brian	1.3	Continue revisions of Province's diligence question list to reflect internal analyses.
18	10/26/2020	Bromberg, Brian	1.0	Perform calculation of illustrative B Side investment returns.
18	10/26/2020	Kim, Ye Darm	1.4	Prepare model to sensitize royalty rates for transfers analysis.
18	10/26/2020	Kim, Ye Darm	0.7	Process additional revisions to the UCC Transfer Review diligence questions.
18	10/26/2020	Kim, Ye Darm	0.9	Process updates to UCC Transfers Review diligence questions.
18	10/26/2020	Kim, Ye Darm	0.7	Review analysis of B-side historical returns estimate.
18	10/26/2020	Bromberg, Brian	2.0	Review and process revisions to Province's transfers diligence question list.

**EXHIBIT C**  
**PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649**  
**DETAIL OF TIME ENTRIES**  
**FOR THE PERIOD OCTOBER 1, 2020 TO OCTOBER 31, 2020**

<b>Task Category</b>	<b>Date</b>	<b>Professional</b>	<b>Hours</b>	<b>Activity</b>
18	10/26/2020	Kurtz, Emma	0.3	Review B-Side balance sheets provided by Huron as backup to the October 2019 asset report.
18	10/26/2020	Bromberg, Brian	0.7	Review B-side trust balance sheets to compare with net asset reports.
18	10/26/2020	Diaz, Matthew	1.1	Review the B side transfers analysis.
18	10/26/2020	Diaz, Matthew	0.9	Review the non cash transfer report and related diligence questions list.
18	10/29/2020	Blonder, Brian	1.0	Calls with FTI IP group and matter team. regarding royalty rates.
18	10/29/2020	Bromberg, Brian	0.6	Finalize and distribute A side transfers diligence questions to Counsel.
18	10/29/2020	Diaz, Matthew	0.5	Participate in a call with the UCC to discuss the non cash transfers report.
18	10/29/2020	Kim, Ye Darm	0.5	Participate in call with Province re: UCC Transfers Review diligence.
18	10/29/2020	Kurtz, Emma	0.7	Participate in call with UCC and Counsel to discuss UCC analysis of historical transfers.
18	10/29/2020	Bromberg, Brian	0.8	Participate in call with UCC on non cash transfers.
18	10/29/2020	Bromberg, Brian	1.0	Participate in discussion on royalties with internal team and distribute relevant historical licensing agreements.
18	10/29/2020	Blonder, Brian	0.5	Preliminary research regarding pharma industry royalty rates.
18	10/29/2020	Bromberg, Brian	2.3	Prepare for call with UCC on non cash transfers.
18	10/29/2020	Bromberg, Brian	1.2	Process revisions to illustrative B side investment return analysis file.
18	10/29/2020	Blonder, Brian	0.9	Review 10/19/2020 presentation document regarding royalty rates.
18	10/29/2020	Kim, Ye Darm	1.3	Review historical notes receivables supporting documents.
18	10/29/2020	Diaz, Matthew	0.6	Review the B side transfers and the investment return analysis.
18	10/29/2020	Diaz, Matthew	0.6	Review the non cash royalty rates used in the Ocean Tomo analysis.
18	10/29/2020	Kim, Ye Darm	0.5	Review updated B-Side implied returns analysis.
18	10/30/2020	Blonder, Brian	1.2	Conduct review of 2002 to 2005 UK license and amendments.
18	10/30/2020	Blonder, Brian	0.4	Correspond with IP team on royalty diligence issues.
18	10/30/2020	Blonder, Brian	0.8	Perform review of current licenses for 5 countries between 2016 to 2018.
18	10/30/2020	Blonder, Brian	0.9	Prepare summary schedule of license agreements reviewed including key deal terms.
<b>18 Total</b>			<b>141.3</b>	
19	10/13/2020	Kim, Ye Darm	0.6	Participate in call re: outstanding diligence workstreams.
19	10/13/2020	Kurtz, Emma	0.4	Review recently uploaded dataroom documents to update dataroom index and share with team.
19	10/14/2020	Kurtz, Emma	0.7	Update dataroom index to include recently received diligence items to share with team.
19	10/16/2020	Bromberg, Brian	0.5	Participate in call re: diligence work plan with internal team.
19	10/16/2020	Kim, Ye Darm	0.6	Participate in call re: outstanding diligence workstreams.
19	10/26/2020	Kurtz, Emma	0.3	Prepare updates to dataroom index to include recently uploaded documents.
<b>19 Total</b>			<b>3.1</b>	
20	10/9/2020	Diaz, Matthew	0.5	Participate on a call with the Debtors' to discuss possible buyers' interest.
20	10/10/2020	Diaz, Matthew	0.6	Participate in a call with PJT to discuss the results of the call with the NCSG.
<b>20 Total</b>			<b>1.1</b>	
21	10/7/2020	Simms, Steven	1.6	Participate in call with AHC on proposed settlement and Sackler investigation progress.
21	10/7/2020	Diaz, Matthew	1.1	Participate in the Purdue AHC call to discuss the Sackler mediation and other topics.
21	10/9/2020	Diaz, Matthew	0.5	Participate in a call with AHC counsel to discuss possible inbound interest.
21	10/13/2020	Diaz, Matthew	1.0	Participate in a call with the AHC to discuss the post emergence structure.
21	10/13/2020	Simms, Steven	1.1	Participate in call re: Presentation on Sackler issues with AHC.
21	10/15/2020	Simms, Steven	0.7	Participate in call with AHC re: ongoing diligence and case issues.
21	10/15/2020	Diaz, Matthew	0.6	Participate in the AHC call to discuss the Sackler mediation, current issues and other topics.
21	10/15/2020	Kim, Ye Darm	0.8	Participate in weekly AHC call to discuss mediation issues and ongoing diligence.
21	10/15/2020	Bromberg, Brian	0.6	Participate in weekly Committee call re: diligence updates.
21	10/21/2020	Kim, Ye Darm	0.9	Participate in AHC call re: ongoing diligence.
21	10/21/2020	Bromberg, Brian	0.7	Participate in weekly Committee call re: diligence updates.
21	10/28/2020	Diaz, Matthew	1.1	Participate in a call with the AHC to discuss the mediation, presentation to be presented to the NCSG re post emergence trust structure and other topics.
21	10/28/2020	Suric, Emil	1.2	Participate in AHC meeting re: diligence updates on product forecasts.
21	10/28/2020	Bromberg, Brian	1.1	Participate in call with AHC re: IAC diligence updates.
21	10/28/2020	Kim, Ye Darm	0.7	Participate in weekly AHC call re: diligence updates.
<b>21 Total</b>			<b>13.7</b>	

**EXHIBIT C**  
**PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649**  
**DETAIL OF TIME ENTRIES**  
**FOR THE PERIOD OCTOBER 1, 2020 TO OCTOBER 31, 2020**

<b>Task Category</b>	<b>Date</b>	<b>Professional</b>	<b>Hours</b>	<b>Activity</b>
22	10/9/2020	Diaz, Matthew	1.9	Participate in a call with the NCSG to discuss the Sackler mediation.
22	10/9/2020	Diaz, Matthew	0.6	Prepare for the call with the non consenting states regarding mediation issues.
22	10/29/2020	Diaz, Matthew	2.3	Participate in a call with the NCSG to discuss the proposed go forward emergence structure.
<b>22 Total</b>			<b>4.8</b>	
24	10/22/2020	Kim, Ye Darm	2.1	Continue to prepare the September Fee Application.
24	10/22/2020	Kim, Ye Darm	2.3	Continue to prepare the September fee application.
24	10/22/2020	Kurtz, Emma	0.4	Prepare revisions to analysis re: fee application write offs to incorporate internal revisions.
24	10/22/2020	Kim, Ye Darm	2.4	Prepare the Purdue September fee application.
24	10/22/2020	Kim, Ye Darm	1.2	Process revisions to the September Purdue fee application.
24	10/22/2020	Diaz, Matthew	0.7	Review the September bill.
24	10/23/2020	Kim, Ye Darm	0.6	Process updates to the August Fee App per comments from Counsel.
24	10/26/2020	Kim, Ye Darm	1.9	Prepare the third interim fee application.
24	10/27/2020	Kim, Ye Darm	1.6	Prepare the third interim fee application.
24	10/28/2020	Kim, Ye Darm	2.6	Prepare the third interim fee application.
24	10/28/2020	Kim, Ye Darm	2.7	Prepare the third interim fee application.
24	10/28/2020	Kim, Ye Darm	1.7	Process revisions to the third interim fee application.
24	10/29/2020	Hellmund-Mora, Marili	0.5	Process the August fee application.
24	10/29/2020	Diaz, Matthew	1.1	Review of the 3rd interim fee application.
<b>24 Total</b>			<b>21.8</b>	
28	9/30/2020	Kim, Ye Darm	1.8	Review the latest IAC model product P&Ls.
28	10/7/2020	Kim, Ye Darm	0.7	Participate in call re: updated IAC business plan.
28	10/7/2020	Bromberg, Brian	1.0	Participate in call with Management Revisions re: latest IAC business plan.
28	10/7/2020	Kurtz, Emma	0.7	Participate in call with Steve Jamieson re: outstanding questions on latest IAC business plan model.
28	10/7/2020	Kim, Ye Darm	0.3	Review financial material re: IAC business plan prior to call.
28	10/12/2020	Diaz, Matthew	1.0	Participate in a call with Deutsche Bank re: the IAC sale process.
28	10/12/2020	Diaz, Matthew	0.5	Participate in a call with the AHC professionals to discuss the IAC due diligence.
28	10/12/2020	Kim, Ye Darm	1.0	Participate in call with Deutsche Bank re: IAC sale process.
28	10/12/2020	Bromberg, Brian	1.1	Participate in call with Deutsche Bank re: IAC sale.
28	10/12/2020	Kurtz, Emma	1.0	Participate in call with Deutsche Bank to discuss IAC sale process.
28	10/12/2020	Bromberg, Brian	0.8	Review the updated IAC business plan financials.
28	10/14/2020	Diaz, Matthew	0.5	Participate in a call with Alix to discuss the IAC tax analysis.
28	10/14/2020	Bromberg, Brian	0.5	Participate in call with Debtor advisors re: IAC tax diligence.
28	10/15/2020	Bromberg, Brian	1.5	Create agenda for upcoming LEK Consulting meeting.
28	10/15/2020	Bromberg, Brian	1.1	Participate in call with LEK Consulting re: IACs.
28	10/15/2020	Kim, Ye Darm	1.0	Participate in call with LEK re: IAC business plan.
28	10/15/2020	Kurtz, Emma	1.0	Participate in call with LEK to review commercial due diligence report and analysis of business plan projections.
28	10/15/2020	Kurtz, Emma	0.4	Prepare detailed summary of call with LEK to share with team.
28	10/16/2020	Diaz, Matthew	0.5	Review notes coming out of the LEK call and related analysis.
28	10/21/2020	Diaz, Matthew	0.5	Participate in a call with counsel to discuss tax efficiency strategies re: the IACs.
28	10/23/2020	Bromberg, Brian	0.9	Create question list for call with IAC CEO.
28	10/23/2020	Diaz, Matthew	0.5	Review the agenda and questions for the call with IAC CEO Marc Princen.
28	10/26/2020	Diaz, Matthew	1.0	Participate in a call with Mundipharma's CEO to discuss the current status of the business.
28	10/26/2020	Diaz, Matthew	0.7	Participate in a call with the Debtors' and AHC's professionals to discuss the ramifications of the IAC CEO call.
28	10/26/2020	Bromberg, Brian	1.2	Participate in call with CEO of Mundipharma.
28	10/26/2020	Kim, Ye Darm	1.0	Participate in call with IAC CEO re: YTD results and strategic initiatives.
28	10/26/2020	Kurtz, Emma	1.0	Participate in call with Marc Princen, Mundipharma CEO, to discuss his initiatives and changes to the business plan.
28	10/26/2020	Bromberg, Brian	0.7	Participate in coordination call with UCC and Debtor advisors re: IACs.
28	10/26/2020	Bromberg, Brian	0.5	Prepare summary of call with the IAC CEO.
28	10/26/2020	Bromberg, Brian	1.2	Review the updated IAC business plan financial information.
28	10/27/2020	Kurtz, Emma	0.9	Prepare revisions to analysis of iterations of IAC business plans to conform with files received from the Company and changes.



**EXHIBIT C**  
**PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649**  
**DETAIL OF TIME ENTRIES**  
**FOR THE PERIOD OCTOBER 1, 2020 TO OCTOBER 31, 2020**

<b>Task Category</b>	<b>Date</b>	<b>Professional</b>	<b>Hours</b>	<b>Activity</b>
28	10/27/2020	Kurtz, Emma	1.1	Review iterations of IAC business plan to evaluate changes to net sales from earlier models to September models.
28	10/27/2020	Bromberg, Brian	1.8	Review prior IAC analyses on sum of the parts valuations.
28	10/27/2020	Diaz, Matthew	0.9	Review the updated IAC operating results.
28	10/27/2020	Bromberg, Brian	1.1	Review YTD IAC financial performance against the business plan.
28	10/27/2020	Kim, Ye Darm	0.8	Review YTD performance against latest IAC business plan.
28	10/28/2020	Bromberg, Brian	1.5	Create summary points for discussion re: IAC diligence status for a call with the AHC.
28	10/28/2020	Bromberg, Brian	0.8	Review and update diligence questions for IACs re: updated business plan.
<b>28 Total</b>			<b>34.5</b>	
<b>Grand Total</b>			<b>465.4</b>	